Purchase Order HT942524P0095

Award Date 7/3/24
Potential Completion Date 8/5/24
Potential Value $76K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Adaptive Biotechnologies Corporation (also doing business as Adaptive) for IMMUNOSEQ MMTCRB SERVICE. The contract, valued at $12,200.00, does not have a set-aside designation. Through this award, Adaptive Biotechnologies will provide specialized sequencing and testing services to support HHS research programs. Adaptive...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed-price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for $37,820.00. The contract is for immunosequencing services, including T-cell receptor alpha/delta (TCRA/D) and B-cell repertoire (HSTCRB) sequencing, to analyze diversity of these cells in primary immunodeficiency research. The award...
This is a $385,920 firm fixed price definitive contract awarded by the Defense Health Agency to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide the ClonoSEQ Minimal Residual Disease In-Vitro Diagnostic Array for the Department of Pathology at the Walter Reed National Military Medical Center. The contract has a performance period ending on February 28, 2025 and does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $14,225.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for immunosequencing extraction services. The contract supports NIH research programs and does not have a set-aside designation. Adaptive has previously provided specialized testing and genomic sequencing services to HHS, the Department...
The Department of Health and Human Services (HHS) National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $61,150.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for SARS-COV-2 immunosequencing testing services. The contract has a performance period through September 30, 2024 and was awarded on May 7, 2024. Adaptive has previously provided specialized testing and genomic sequencing services to HHS,...
This is a firm fixed-price purchase order issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (doing business as Adaptive) for $6,200. The contract is for repertoire sequencing services, which involve analyzing the adaptive immune system's T-cell and B-cell receptors. This award supports NIAID's research programs. Adaptive, a commercial provider of immune-driven medicine,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $20,197.60 firm-fixed-price purchase order for DNA sequencing services to Adaptive Biotechnologies Corporation, doing business as Adaptive. The contract has no set-aside designation and was completed on June 21, 2019. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts from the...
This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide ClonoSEQ minimal residual disease testing services for the Boston and West Haven VA health care systems. The contract has a ceiling value of $95,000.00 and a period of performance through July 2026. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, and...
This is a $12,300 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (Adaptive) for "IMMUNOSEQ MMTCRB SEQUENCING SERVICE". The contract has an ultimate completion date of December 31, 2023 and was awarded on September 19, 2023 without a set-aside designation. Adaptive, a for-profit organization, has previously...
This firm fixed-price federal contract award is for the provision of IMMUNOSEQ MMTCRB SEQUENCING SERVICE (DEEP) by Adaptive Biotechnologies Corporation, doing business as Adaptive, to the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The $10,400.00 contract has a completion date of July 3, 2024. Adaptive Biotechnologies is an established provider of immune-driven medicine services and products to federal...

The U.S. Defense Health Agency (DHA) has awarded a $76,200 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for adaptive immunosequencing services. The award does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products. The company has previously received awards from the Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) to provide specialized testing and genomic sequencing services, including T-cell and B-cell repertoire sequencing, ClonoSEQ minimal residual disease testing, and related analytics. The current award supports DHA research programs and has an ultimate completion date of August 5, 2024.

Generated 1/16/25, 9:14 AM